Our work demonstrates the critical role Tiam1 plays in the pathophysiology of chronic pain–induced mood dysregulation and the sustained antidepressant-like effects of ketamine, revealing it as a potential therapeutic target for the treatment of comorbid mood disorders in chronic pain. Here, TIAM1 is linked to mood disorder.